

AMIDD Lecture 8: Pharmacokinetic and Pharmacodynamic Modelling




Fig. 1.
Major components of mechanism-based PK/PD models.

Mager, Donald E., Sukyung Woo, and William J. Jusko. 2009. "Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans." *Drug Metabolism and Pharmacokinetics* 24 (1): 16–24.

Dr. Jitao David Zhang, Computational Biologist


¹ *Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche*

² *Department of Mathematics and Informatics, University of Basel*

Topics

- **Pharmacokinetic (PK) modelling**
- **Joint pharmacokinetic-pharmacodynamic (PK-PD) modelling**
- **PBPK modelling**



Questions in preclinical development: what to give, how to give, how much, and how often?




Adapted from Paul *et al.* "How to Improve R&D Productivity: The Pharmaceutical Industry's Grand Challenge." *Nature Reviews Drug Discovery*, 2010

Pharmacokinetic and pharmacodynamic modelling


- Pharmacokinetics (PK) describes how the drug is absorbed, distributed, metabolised, and excreted by the body. The ADME properties are affected by physicochemical properties of the drug, and other properties such as human behavior (e.g. food and drug intake) and genetics.
- Pharmacodynamics (PD) describes the effect of the drug to the body, mediated by drug-target interactions. PD is affected by PK, as well as other properties such as behaviour and genetics.
- A basic mathematical model of PK is a compartment model that can be transcribed as a set of differential equations that describe the relationship between drug concentration and time.
- PD models can have versatile forms, for instance a linear model, or a non-linear model (e.g. Hill's function), a compartment model, or other forms.



(a) PK model



(b) PD model




(c) Combined PK/PD model

Mortensen, Stig Bousgaard, Anna Helga Jónsdóttir, Søren Klim, and Henrik Madsen. 2008. "Introduction to PK/PD Modelling - with Focus on PK and Stochastic Differential Equations." Technical University of Denmark, DTU Informatics.

Principles of absorption

Absorption

- Sometimes preceded by the process of *liberation*, the release of the active component from the formulation
- Process by which a drug compound transfers from an extravascular site of dosing (e.g. gut, lung, muscle, and skin) into systemic circulation, known as the **central compartment**.
- Intravenous administration in a *bolus* dose (single dose, short time) can be modelled as instant absorption. Infusion using a constant rate over time can be modelled as instant absorption by time.
- Extravascular dosing, for instance (a) oral (b) injection into muscle or fat tissue, needs to be absorbed. During this process the drug concentration may reduce due to metabolism and trapping. The ratio between active drug concentration reaching the central compartment and the in-take concentration is known as the **bioavailability**.




Psychopharmacology, Figure 1.2

Principles of distribution

Distribution

- Following absorption, drug molecules are distributed into organs and tissues.
- Different organs and tissues receive different doses of the drug, and the concentration-time relationship also varies.
- Distribution of a drug in a tissue depends on both **physiological factors**, including the vascular permeability, blood flow, the perfusion rate of the tissue, and **physicochemical properties of the drug**, including plasma protein binding, and lipophilicity.
 - Example 1: Liver and kidney are better perfused than muscle and fat, and the brain is usually inaccessible due to the blood-brain barrier.
 - Example 2: Only free compounds that are not bound to plasma proteins can exert pharmacological functions. Compounds with excessive protein binding have a delayed distribution.

We use the Volume of distribution, V_D , to describe the extent of a drug distribution. The larger the value is, the better the distribution to tissues. A value larger than human circulation volume (0.08 l/kg) is possible, which indicates good distribution in the tissues.



Major components of drug distribution, [U Waterloo](#)

$$V_D = \frac{\text{total amount of drug in the body}}{\text{drug blood plasma concentration}}$$

Principles of metabolism and excretion, which together contribute to *clearance*


Metabolism

- Drug metabolism serves defense against xenobiotics. It facilitates the excretion of the drug by making it hydrophilic. It happens mainly in liver and, for oral drugs, in intestine.
- Drug metabolism can deactivate a compound (very often the case) or activate a compound, turning a **pro-drug** into its active form, e.g. codeine to morphine, below).
- Drug metabolism varies between individuals, between ages in the same individual, and can be affected by drugs as well. Drugs that induce or repress drug-metabolism genes (e.g. cytochrome P450, CYPs) can cause drug-drug interaction.



Excretion

- Excretion follows metabolism and removes drugs and their metabolites from the body.
- The main excretion route is the **urinary** and **biliary** (thereby with feces) **excretion**.
- Urinary excretion include three components: glomerular filtration, secretion, and reabsorption.
- Patients with kidney diseases may have reduced excretion, calling for adjusted dosing.




Modelling pharmacokinetics with ADME properties

Why ADME properties matter?

- They determine how much drug is found where at which time point. The ADME properties, given the pharmacodynamics and off-target effects of the drug, determine the efficacy and safety profiles of a drug.
- Animal ADME parameters can contribute to estimation and inference of human parameters, which contribute to dosing regimen selection with the help of modelling and simulation (how much? how often? etc.)

How are ADME properties determined and predicted?

- *In-vitro* assays, for instance permeability (the PAMPA assay), and hepatic clearance (hepatocyte or microsomal assay).
- QSAR/machine-learning models trained with molecular descriptors and *in-vitro* assay results, for instance for V_d , which is well predictable.
- *In-vivo* measurements



Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination




Mathematical modelling of PK: one-compartment model, bolus

We denote the concentration of the drug as A , and the rate of clearance (metabolism and excretion) as K . Assuming a bolus dose, according to the law of mass action and first-order kinetics, we can write

$$\frac{dA}{dt} = -K \cdot A$$

When we denote the initial dose as A_0 , we can express the general solution of the model as

$$A_{bolus}(t) = A_0 \exp(-K \cdot t)$$



(Left) simulation from *Introduction to PK/PD Modelling - with Focus on PK and Stochastic Differential Equations* (Right) empirical data of propacetamol HCl (IV, intravenous) and paracetamol (PO, per os, oral).

Propacetamol is a pro-drug of paracetamol. The chemical modification (esterification) makes it more water soluble, allowing it delivered via IV.

Question: what is the half-life of the drug, $t_{1/2}$, the time it takes for reducing the amount of drug left in the body by 50%?

One-compartment model, oral dosing



For oral dosing, an extra gut compartment (right) is often sufficient to model the absorption phase

$$\frac{dA_{gut}}{dt} = -K_a \cdot A_{gut}$$

Suppose rate the absorption of the drug is faster than the elimination process ($K_a > K$), we can model the concentration in the central compartment as

$$\frac{dA}{dt} = \overbrace{F \cdot K_a \cdot A_{gut}}^{\text{from gut}} - \overbrace{K \cdot A}^{\text{elimination}}$$

In reality, we cannot easily assess the concentration of drug in the gut. Is it possible to derive the relationship between central-compartment concentration A and time t given the initial condition? The answer is yes: we can find the expression of $A(t)$ analytically in a closed form using the trick of *Laplace transformation*.



Solving the two-equation system with Laplace transform

System: Letting $A_a(t)$ be the amount of drug at the absorption site at time t

$$\begin{aligned}\dot{A}(t) &= k_a A_a(t) - k_e A(t) \\ \dot{A}_a(t) &= -k_a A_a(t)\end{aligned}$$

with initial conditions $A_a(0) = A_{a0} = FD$, $A(0) = A_0 = 0$, where F is the fraction available (take $F \equiv 1$ for simplicity)

Laplace transform of $A(t)$: $\mathcal{L} A = \int_0^\infty e^{-st} A(t) dt$

$$s\mathcal{L} A - A_0 = k_a \mathcal{L} A_a - k_e \mathcal{L} A \quad (1)$$

$$s\mathcal{L} A_a - A_{a0} = -k_a \mathcal{L} A_a \quad (2)$$

- Solve (2) for $\mathcal{L} X_a$ and substitute in (1) to obtain

$$\mathcal{L} A = \frac{k_a F D}{(s + k_e)(s + k_a)}$$

- From a table of Laplace transforms, we find immediately that

$$A(t) = \frac{k_a F D}{k_a - k_e} \{e^{-k_e t} - e^{-k_a t}\}$$

so that (divide by V)

$$C(t) = \frac{k_a F D}{V(k_a - k_e)} \{e^{-k_e t} - e^{-k_a t}\}$$

Marie Davidian, MA/ST 810, *Mathematical-Statistical Modeling and Analysis of Complex Systems*, NC State University

See more about the Laplace transform and other numeric transforms in Bracewell, R. N. 1990. [“Numerical Transforms.” Science 248 \(4956\): 697–704.](#)

One-compartment model, oral (or extravascular) dosing

$$A_{oral}(t) = \frac{K_a F A_0}{K_a - K} (\exp(-K \cdot t) - \exp(-K_a \cdot t))$$

replacing amount with
concentration

$$C_{oral}(t) = \frac{A_{oral}(t)}{V} = \frac{K_a F A_0}{V(K_a - K)} (\exp(-K \cdot t) - \exp(-K_a \cdot t))$$

solving by differentiation

$$t_{max} = \frac{1}{K_a - K} \ln \left(\frac{K_a}{K} \right)$$



replacing t with t_{max}

$$C_{max,oral} = \frac{K_a F A_0}{V(K_a - K)} (\exp(-K \cdot t_{max}) - \exp(-K_a \cdot t_{max}))$$


simplification

$$C_{max,oral} = \frac{F A_0}{V} \exp(-K \cdot t_{max})$$

- The parameter t_{max} describes the time to reach the maximum plasma concentration of the drug since dosing.
- The parameter C_{max} describes the maximum plasma concentration of the drug.



Simulated PK profile of 1000mg paracetamol (PO)



Empirical PK profile of 1000mg paracetamol (PO)

Constant-rate infusion and multiple dosing

We can administer the drug with infusion over time. If we assume a constant infusion amount R_{in} and a constant clearance constant CL , we can derive the analytical solution of drug concentration with regard to time.

- **Question:** what form does it have?

If a pill releases its active ingredient gradually, its plasma concentration can be effectively equivalent to that of a constant-rate infusion. If multiple pills are taken with time intervals, the constant R_{in} can be expressed as a product of bioavailability F and initial dose A_0 , divided by the time interval of taking pills τ . The concentration of **multiple dosing (MD)** can be expressed as the sum of individual dosing profiles (N indicates the number of doses)

The system reaches equilibrium when the infusion rate equals the clearance rate ($dC/dt=0$). Therefore we can deduce the concentration at steady state C_{ss} by the ratio of infusion rate and clearance. Due to the exponential distribution, 90% of the steady-state concentration is reached after 3-4 half-lives.

$$\frac{dC}{dt} = \frac{R_{in}}{V} - \frac{CL}{V} \cdot C$$


$$C(t) = \frac{R_{in}}{CL} \left[1 - \exp\left(-\frac{CL}{V}t\right) \right]$$

$$R_{in} = \frac{F \cdot A_0}{\tau}$$

$$C_{MD}(t) = \sum_{n=0}^{N-1} C_{oral}(t - n\tau)$$

$$\frac{R_{in}}{V} = \frac{CL}{V} C_{ss}$$

$$C_{ss} = \frac{R_{in}}{CL}$$




Multiple dosing of paracetamol, with 4 oral doses of 1g per dose, shown as a thick line. The dotted line is the constant rate infusion at a corresponding rate.


Two-compartment model

A piecewise linear relationship between logarithm-transformed concentration and time often indicates that one-compartment model is not sufficient. Multi-compartment models can be used in these cases.

Similar to one-compartment model, we can set up two differential equations describing the compartment model. The solution has the general form of a weighted sum of two exponentially distributed variables.



suggests




$$\begin{aligned}\frac{dC_1}{dt} &= K_{21} \cdot C_2 - K_{12} \cdot C_1 - K \cdot C_1 \\ \frac{dC_2}{dt} &= K_{12} \cdot C_1 - K_{21} \cdot C_2\end{aligned}$$

solution


$$C = A \cdot \exp(-\alpha t) + B \cdot \exp(-\beta t)$$

$$t_{1/2,\alpha} = \frac{\log(2)}{\alpha} \quad t_{1/2,\beta} = \frac{\log(2)}{\beta}$$

The propacetamol data that we seen before may be modelled by a two-compartment model.



The simplest joint PK/PD model: a binary PD model with a step function





Pharmacokinetic-pharmacodynamic indices of a theoretical drug molecule. MIC: Minimum inhibitory concentration (MIC).

Yu, Yichao, Diether Rüppel, Willi Weber, and Hartmut Derendorf. 2018. "[PK/PD Approaches](#)." In Drug Discovery and Evaluation: Methods in Clinical Pharmacology.

An example of joint PK/PD model of an oral dose of 1000mg paracetamol

- PD models have many forms. The example is taken from Mortensen *et al.* and Gibb and Anderson (2008). It uses a hypothetical effect compartment with an E_{max} model (the Hill function that we introduced before) to model the effect. It does not influence of the PK model.
 - Question: what good the effect compartment do?
- The effect is measured on a visual analogue scale (VAS) from 0-10 where a reduction indicates pain relief.



PK model

$$\begin{aligned} \frac{dC_{gut}}{dt} &= -K_a C_{gut} \\ \frac{dC_1}{dt} &= -k_{12} C_1 + k_{21} C_2 - k_{10} C_1 + F K_a C_{gut} \\ \frac{dC_2}{dt} &= k_{12} C_1 - k_{21} C_2 \end{aligned}$$


Effect compartment

$$\frac{dC_e}{dt} = k_{e1} C_1 - k_{e0} C_e$$

PD model


$$\text{Effect} = 10 - \frac{E_{max} C_e}{EC_{50} + C_e}$$

Physiologically based pharmacokinetic (PBPK) models




(Left) A semi-physiological model (Right) A fully physiology-based PK model

Right figure: Jones, H. M., and K. Rowland-Yeo. 2013. “[Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development](#).” CPT: Pharmacometrics & Systems Pharmacology 2 (8): 63.



PBPK is usually performed in an iterative “learn, confirm, and refine” approach. Initially, the PBPK simulation is performed in animals using animal PBPK models, animal *in vitro* data, and compound physicochemical data. The animal simulation is compared with the *in vivo* data, if this simulation in animals is reasonable, then the healthy volunteer simulation is performed using a human PBPK model. These simulations can then be extended to various patient populations using relevant physiology. If the simulation at any stage is inaccurate, further experiments may be performed to understand the mismatch and to improve the PBPK model.

An industrial PK modelling workflow: example of AstraZeneca



Davies, Michael, *et al.*. 2020. [“Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades.”](#) Trends in Pharmacological Sciences 41 (6): 390–408.

Offline activities

1. Anonymous feedback form: <https://forms.gle/3e9f7xmYngehsv8M6>
2. Optional reading
 - a. Davies, Michael, *et al.*. 2020. “[Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades](#).” Trends in Pharmacological Sciences 41 (6): 390–408. *A good introduction to prediction of PK profiles in industry.*
 - b. Jones, H. M., and K. Rowland-Yeo. 2013. “Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development.” CPT: Pharmacometrics & Systems Pharmacology 2 (8): 63. <https://doi.org/10.1038/psp.2013.41>. *A good introduction to PBPK modelling*

Presentation topics and references



1. Phenotypic screening:

- a. Kleinstreuer, Nicole C., Jian Yang, Ellen L. Berg, Thomas B. Knudsen, Ann M. Richard, Matthew T. Martin, David M. Reif, et al. 2014. “**Phenotypic Screening of the ToxCast Chemical Library to Classify Toxic and Therapeutic Mechanisms.**” *Nature Biotechnology* 32 (6): 583–91. <https://doi.org/10.1038/nbt.2914>.
- b. Moffat, John G., Fabien Vincent, Jonathan A. Lee, Jörg Eder, and Marco Prunotto. 2017. “**Opportunities and Challenges in Phenotypic Drug Discovery: An Industry Perspective.**” *Nature Reviews Drug Discovery* 16 (8): 531–43. <https://doi.org/10.1038/nrd.2017.111>.
- c. Swinney, David C., and Jason Anthony. 2011. “**How Were New Medicines Discovered?**” *Nature Reviews Drug Discovery* 10 (7): 507–19. <https://doi.org/10.1038/nrd3480>.

2. Machine learning

- a. Vamathevan, Jessica, Dominic Clark, Paul Czodrowski, Ian Dunham, Edgardo Ferran, George Lee, Bin Li, et al. 2019. “” *Nature Reviews Drug Discovery* 18 (6): 463. <https://doi.org/10.1038/s41573-019-0024-5>. **Applications of Machine Learning in Drug Discovery and Development.**
- b. Yang, Kevin K., Zachary Wu, and Frances H. Arnold. 2019. “**Machine-Learning-Guided Directed Evolution for Protein Engineering.**” *Nature Methods* 16 (8): 687. <https://doi.org/10.1038/s41592-019-0496-6>.
- c. McCloskey, Kevin, Eric A. Sigel, Steven Kearnes, Ling Xue, Xia Tian, Dennis Moccia, Diana Gikunju, et al. 2020. “**Machine Learning on DNA-Encoded Libraries: A New Paradigm for Hit Finding.**” *Journal of Medicinal Chemistry*, June. <https://doi.org/10.1021/acs.jmedchem.0c00452>.

3. Productivity and cost of drug discovery and development

- a. Dickson, Michael, and Jean Paul Gagnon. 2004. “**Key Factors in the Rising Cost of New Drug Discovery and Development.**” *Nature Reviews Drug Discovery* 3 (5): 417. <https://doi.org/10.1038/nrd1382>.
- b. Paul, Steven M., Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacy R. Lindborg, and Aaron L. Schacht. 2010. “**How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge.**” *Nature Reviews Drug Discovery* 9 (3): 203–14. <https://doi.org/10.1038/nrd3078>.
- c. Waring, Michael J., John Arrowsmith, Andrew R. Leach, Paul D. Leeson, Sam Mandrell, Robert M. Owen, Garry Pairaudeau, et al. 2015. “**An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies.**” *Nature Reviews Drug Discovery* 14 (7): 475–86. <https://doi.org/10.1038/nrd4609>.

4. Mathematical biology

- a. Allen, Richard, and Helen Moore. 2019. “**Perspectives on the Role of Mathematics in Drug Discovery and Development.**” *Bulletin of Mathematical Biology*, January, 1–11. <https://doi.org/10.1007/s11538-018-00556-y>.
- b. Turing, Alan Mathison. 1952. “**The Chemical Basis of Morphogenesis.**” *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences* 237 (641): 37–72.
- c. Tuszynski, Jack A, Philip Winter, Diana White, Chih-Yuan Tseng, Kamlesh K Sahu, Francesco Gentile, Ivana Spasevska, et al. 2014. “**Mathematical and Computational Modeling in Biology at Multiple Scales.**” *Theoretical Biology & Medical Modelling* 11 (December). <https://doi.org/10.1186/1742-4682-11-52>.

Summary and Q&A